Trial Parameters
Brief Summary
Pipelle is the most commonly used outpatient endometrial biopsy device. Pipelle endometrial biopsy can diagnose 90% of endometrial cancer cases. Pipelle endometrial biopsy is one of the first-line diagnostic procedures for women presenting with abnormal peri- and post-menopausal vaginal bleeding. Insufficient samples are obtained in 5-23% of cases. In Adan Hospital, a retrospective analysis of all outpatient endometrial samples sent to the histopathology department from April- to October 2024 study showed an insufficient sample percentage of 32% This may be attributed to factors such as patients, equipment, and physicians. This project aims to improve the endometrial biopsy results by Identifying these factors in the Adan hospital setting, Implementing measures to modify these factors, and finally re-auditing the endometrial biopsy results after six months.
Eligibility Criteria
Inclusion Criteria: * All patients undergoing outpatient endometrial biopsy in the specified time interval (11/2024- 4/2025) will be included. Exclusion Criteria: * Could not obtain the sample due to patient physicals, anxiety (patient decline), cervical stenosis, or severe bleeding